



Spring Group Meeting

San Francisco Specials

APRIL 30 - MAY 2, 2026



Leukemia Committee

Leukemia Committee

Leadership

Chair: Harry P. Erba, MD, PhD
 Vice-Chair: Anjali S. Advani, MD
 Executive Officer:..... Alex Herrera, MD
 Statisticians: Megan Othus, PhD
 Anna Moseley, MS
 Matt Chansky, BS

Scientific Leadership

Translational Medicine:..... Jerald P. Radich, MD
 Pathology: David R. Head, MD
 Radiation Oncology:..... Austin Sim, MD
 Cytogenetics Liaison:..... Min Fang, MD, PhD

Designates

Cancer Control:..... Stephanie B. Tsai, MD
 Veterans Affairs: Tsewang Tashi, MD
 Data Coordinators: Roula Bustami
 Louise Highleyman, BA
 Cassie Villasin
 Oncology Research Professionals: Breanne Burke, BS
 Callie Wiskus, BS, CCRP
 Patient Advocate:..... Gail Sperling, MPH
 Pharmaceutical Science:..... Holly O. Chan, PharmD
 Yumena Kawasaki, PharmD
 Protocol Project Manager:..... Amy Doyle
 Protocol Project Manager:..... Samantha Bankston (MyeloMATCH)
 Clinical Trials Program Manager:..... Sharon Palmer
 Clinical Trials Program Manager:..... Sarah Cantu (MyeloMATCH)

Time/Location

Thursday, April 30, 2026 5:15 p.m. - 7:15 p.m.
 Room: Garden Room (Atrium Lobby Level)

Agenda

1. Updates in Leukemia Translational Medicine - Cecilia Yeung
2. Updates in ALL - Ibrahim Aldoss
3. MyeloMATCH - Laura Michaelis
4. Updates in CLL - Debbie Stephens and Mazyar Shadman

AML/MDS Studies

Closed Studies

S1612, "A Randomized Phase II/III Trial of "Novel Therapeutics" Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older." Drs. L. Michaelis, R. Walter, S. Assouline, et al. Activated: 12/22/17; Complete: 6/26/24.

S0919, "A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Poor-Risk Acute Myelogenous Leukemia (AML)." Dr. A. Advani. Re-Activated: 4/1/13; Closed: 9/15/17; Complete: 10/21/21.

S1203, "A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)." Drs. Garcia-Manero and Pagel. Activated: 12/15/12; Closed: 11/4/15; Complete: 03/29/22.

CTS/A041701, "A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy." Dr. L. Liesveld. Activated: 1/16/19. Closed: 9/16/24.

ALL Studies

Active Studies

S1905, "A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) / T-Cell Lymphoblastic Lymphoma (T-LBL)." Drs. A. Advani, N. Papadantonakis, and C. Yeung. Activated: 8/17/20.

CTS/A041501, "A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL." Dr. A. Advani. Activated: 6/1/17. Temporarily closed to accrual: 1/16/26.

Developing Studies

S2507, "A Phase II Randomized Study of Blinatumomab with or without Revumenib for Patients with KMT2Ar B-ALL with persistent measurable residual disease (MRD)." Drs. I. Aldoss, A. Advani, W. Stock, J. McNeer, and C. Saygin.

Leukemia Committee

Closed Studies

S0333, “A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia with Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy.” Drs. Forman and O’Donnell. Activated: 4/15/05; Closed: 11/1/09.

S1312, “A Phase I Study of Inotuzumab Ozogamicin in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt’s Leukemia).” Drs. A. Advani and Liedtke. Activated: 4/1/14; Closed: 8/2/19.

S1318, “A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphocytic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients ≥ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL and Philadelphia-Chromosome-Like Signature (Ph-like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF).” Drs. A. Advani and K. O’Dwyer. Activated: 1/12/15; Closed: 9/29/21.

CLL Studies

Active Studies

S1925, “Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL): EVOLVE CLL/SLL Study.” Drs. D. Stephens, B. Hill, J. Pagel, et al. Activated: 12/14/20.

Developing Studies

S2504, “A Randomized Phase II Study of Pirtobrutinib Plus R-CHOP vs. R-CHOP for Patients with Previously Untreated Richter Transformation (RT).” Drs. M. Shadman, D. Stephens, and A. Danilov.

Closed Studies

CTSUA041702, “A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL).” Dr. M. Shadman. Activated: 1/3/19. Closed: 4/30/21.

CTSUA041702, “A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL).” Dr. B. Hill. Activated: 1/4/19. Closed: 7/15/22.

CML Studies

Closed Studies

S1712, “A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease.” Drs. K. Sweet and J. Radich. Activated: 7/20/18. Closed: 10/20/22.

MDS/MPN Studies

Developing Studies

S2603 “A Phase II Study of Nuvisertib and Decitabine-Cedazuridine for Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs).” Drs. A. Coltoff, A. Gerds, and F. El Chaer.

MyeloMATCH

Active Studies

MYELOMATCH, “Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials.” Drs. J. Radich and S. Jiwani. Activated: 5/16/24.

MM1YA-S01, “A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs. (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger who are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by myeloMATCH; A myeloMATCH Clinical Trial.” Drs. P. Shami and T. Lin. Activated: 5/16/24.

MM10A-S03, “A Randomized Phase II trial of C-DEC, Venetoclax, and Enasidenib Compared with Azacitidine and Venetoclax for Newly Diagnosed Older Adults with IDH2 mutant AML: A myeloMATCH Substudy.” Drs. E. Huselton and U. Borate. Activated: 4/1/25

Developing Studies

MM10A-S04, “A Phase II Trial of ASTX727 with Standard Duration Versus Shorter Duration of Venetoclax in Genomically Heterogenous AML Among Adults Aged 60 or Older and Less Fit for Intensive Therapy: A myeloMATCH Substudy.” Drs. U. Borate and J. Jayanshu.

Leukemia Committee

MM10A-S05, "A RAS-Activated Biomark Driven Phase II Study Evaluating the Addition of Tuspetinib to CPX-351 Induction Therapy in Older Fit Adults with Acute Myeloid Leukemia: A myeloMATCH Substudy." Drs. J. Appelbaum, B. Jonas, and M. Konopleva.

Mullighan. *Nat Cancer*. 2025 Jul;6(7):1242-1262. doi: 10.1038/s43018-025-00987-2. Epub 2025 Jun 27. NIHMS2100933.
<https://pubmed.ncbi.nlm.nih.gov/40579588/>

MM1-S06, "A Phase II Study of Novel Agents with Venetoclax and the DNMT1 Inhibitor Cedazuridine-Decitabine for Newly Diagnosed Acute Myeloid Leukemia/Myelodysplastic Syndromes with TP53 Mutations (NAVIGATE-TP53): A myeloMATCH Substudy." Drs. R. Shallis, E. Winer, D. Sallman.

Submitted Manuscripts

None this cycle

Clinical Trials Partnerships (CTP)

Active Studies

21CTP.LEUK01, "A Phase II Trial of Asciminib, Dasatinib, Prednisone, and Blinatumomab for Participants with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia." Drs. Advani, Liedtke and Radich. Activation: 5/15/25

Developing Studies

26CTP.LEUK02, "A Randomized Open Label Trial Comparing Momelotinib vs Dose-Adjusted Ruxolitinib for Treatment-Naive, Cytopenic Myelofibrosis." Drs. Coltoff, Gerds, Borate, and Chen.

Publications

The publication papers listed below from 2025 and 2026 have not appeared in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

Published/Accepted Manuscripts

S1203 Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive induction chemotherapy: Secondary analysis of SWOG S1203 . S Raychaudhuri, M Othus, M Percival, G Garcia-Manero, F Appelbaum, H Erba, J Appelbaum. *Blood Neoplasia* Jun 14;2(3):100129.
<https://pubmed.ncbi.nlm.nih.gov/40792015/>

Multiple Studies Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features. Ilaria Iacobucci, Andy G X Zeng, Qingsong Gao, Laura Garcia-Prat, Pradyumna Baviskar, Sayyam Shah, Alex Murison, Veronique Voisin, Michelle Chan-Seng-Yue, Cheng Cheng, Chunxu Qu, Colin Bailey, Matthew Lear, Matthew T Witkowski, Xin Zhou, Airen Zaldivar Peraza, Karishma Gangwani, Anjali S Advani, Selina M Luger, Mark R Litzow, Jacob M Rowe, Elisabeth M Paietta, Wendy Stock, John E Dick, Charles G

Leukemia Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1905	S1925	MYELOMATCH	MM1YA-S01	MM10A-S03	MM10A-EA02	MM1YA-CTG01	A041501
Banner University Medical Center - Tucson	-	1	5	1	-	1	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	6	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	2	7	-	-	-	-	-	4
Cancer Research for the Ozarks NCORP	-	1	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	5	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	1	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	3	-	-	1	1	-
Cedars-Sinai Medical Center	-	-	4	-	-	2	-	-
City of Hope Comprehensive Cancer Center	6	2	-	-	-	-	-	-
Dartmouth College - Dartmouth Cancer Center LAPS	-	1	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	1	7	3	1	1	-	-
Essentia Health NCI Community Oncology Research Program	-	1	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	4	3	-	-	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	11	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	12	-	1	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	3	-	-	-	-	-
Henry Ford Hospital	-	3	6	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	-	-	-	-	2
Kaiser Permanente NCI Community Oncology Research Program	-	2	-	-	-	-	-	-
Loyola University Medical Center	-	1	12	-	1	3	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	5	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	5	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	7	19	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	1	-	-	-	-	-
Mount Sinai Hospital	-	-	-	1	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	16	3	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	1	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	-	-

Leukemia Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1905	S1925	MYELOMATCH	MM1YA-S01	MM10A-S03	MM10A-EA02	MM1YA-CTG01	A041501
Northwestern University LAPS	-	1	33	2	-	-	-	3
Ohio State University Comprehensive Cancer Center LAPS	-	-	9	2	-	-	-	-
Oregon Health and Science University	1	-	6	1	-	-	-	8
Our Lady of the Lake Hospital	-	-	2	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	1	27	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	1	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	2	-	-	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	-	-	-	-	-	8
UC Davis Comprehensive Cancer Center LAPS	-	4	3	-	-	-	-	2
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	4	-	-	-	-	-	3
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	6	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	41	4	-	-	1	1
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	2	-	-	-	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	1	43	5	-	-	3	-
University of Kentucky/Markey Cancer Center	-	-	5	-	-	2	-	-
University of Nebraska Medical Center	-	-	3	1	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	5	-	-	-	-	-
University of Rochester LAPS	4	14	53	5	-	3	1	7
University of Utah - Huntsman Cancer Institute LAPS	-	21	9	-	-	-	-	1
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	11	2	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	7	1	-	1	-	5
ALLIANCE	2	49	206	9	-	-	-	-
CCTG	-	14	56	-	-	-	-	-
COG	1	-	-	-	-	-	-	-
ECOG-ACRIN	2	18	186	12	3	-	-	-
NRG	-	6	35	1	2	-	-	-
Total	24	172	862	53	8	14	6	44

Leukemia Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	A041701	A041703	A042001	EA9152	EA9171	EA9181	EA9213
Banner University Medical Center - Tucson	-	-	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-
Dartmouth College - Dartmouth Cancer Center LAPS	-	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-	-	3	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	3
Froedtert and the Medical College of Wisconsin LAPS	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	4	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-
Henry Ford Hospital	4	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	3	-
Intermountain Medical Center	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	-	3	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-
Northwell Health NCORP	2	-	-	-	-	-	-

Leukemia Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	A041701	A041703	A042001	EA9152	EA9171	EA9181	EA9213
Northwestern University LAPS	1	-	1	-	-	4	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-
Oregon Health and Science University	-	-	-	-	-	-	-
Our Lady of the Lake Hospital	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	3	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	1	-	-	-	12	-
UC San Diego Moores Cancer Center	-	-	-	-	-	2	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	2	-	-	-	-
University of Arkansas for Medical Sciences	4	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	1	-	-	-	4	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-
University of Nebraska Medical Center	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-
University of Rochester LAPS	27	3	4	-	-	13	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	3	-
Western States Cancer Research NCORP	-	-	-	-	2	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	2	3	2	1	-
ALLIANCE	-	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-
COG	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-
Total	38	5	12	3	4	52	3

